# OnCo record nct05601752 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05601752/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05601752", "NCT05601752" ;
  schema:name "ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)"@en ;
  schema:alternateName "SURPASS-3"@en ;
  schema:description "A phase 2 trial of Nivolumab in ovarian cancer, run by USWM CT, LLC, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05601752/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05601752> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2023-06-26" ;
  onco:cancers <https://onco.cc/cancers/ovarian/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/> .